Table 1

Drug classes receiving co-payment reductions: focus on diabetes trial

Glycemic Agents

Metformin

Sulfonylureas

Thiazolidinediones

All other glycemic agents (except insulin*)

Antihypertensive Agents

ACE-Inhibitors & Angiotensin Receptor Blockers (ACE/ARB)

Beta blockers

Calcium Channel Blockers

Diuretics

Other antihypertensives

Lipid-Lowering Agents

HMG-CoA Reductase Inhibitors (statins)

Zetia

Other lipid lowering agents

Antidepressants

SSRSs/SNRIs

Tricyclic agents

Other antidepressants


*At the time of the intervention, M-CARE already waived copayments for Insulin.

Spaulding et al. Implementation Science 2009 4:19   doi:10.1186/1748-5908-4-19

Open Data